Figure S5 from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Abstract

Combination of MEK inhibitor with venetoclax in primary patient samples and KOPN-8 cells.